These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 27532449)

  • 1. Adherence to agents acting on the renin-angiotensin system in secondary prevention of non-fatal myocardial infarction: a self-controlled case-series study.
    Ortolani P; Di Bartolomeo S; Marino M; Vagnarelli F; Guastaroba P; Rapezzi C; De Palma R
    Eur Heart J Cardiovasc Pharmacother; 2015 Oct; 1(4):254-9. PubMed ID: 27532449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-controlled case-series study to verify the effect of adherence to Beta-blockers in secondary prevention of myocardial infarction.
    Di Bartolomeo S; Marino M; Guastaroba P; Valent F; De Palma R
    J Am Heart Assoc; 2015 Jan; 4(1):e001575. PubMed ID: 25567050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of renin-angiotensin system inhibitors on long-term survival in patients treated with beta blockers and antiplatelet agents after acute myocardial infarction (from the MONICA/KORA Myocardial Infarction Registry).
    Amann U; Kirchberger I; Heier M; Zirngibl A; von Scheidt W; Kuch B; Peters A; Meisinger C
    Am J Cardiol; 2014 Aug; 114(3):329-35. PubMed ID: 24927969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.
    Halvorsen S; Jortveit J; Hasvold P; Thuresson M; Øie E
    BMC Cardiovasc Disord; 2016 May; 16():115. PubMed ID: 27246583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction.
    Korhonen MJ; Robinson JG; Annis IE; Hickson RP; Bell JS; Hartikainen J; Fang G
    J Am Coll Cardiol; 2017 Sep; 70(13):1543-1554. PubMed ID: 28935030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction.
    Arnold SV; Spertus JA; Masoudi FA; Daugherty SL; Maddox TM; Li Y; Dodson JA; Chan PS
    J Am Coll Cardiol; 2013 Nov; 62(19):1791-801. PubMed ID: 23973701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
    Shore S; Jones PG; Maddox TM; Bradley SM; Stolker JM; Arnold SV; Parashar S; Peterson P; Bhatt DL; Spertus J; Ho PM
    Heart; 2015 May; 101(10):800-7. PubMed ID: 25801001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication use in long-term survivors from the MONICA/KORA Myocardial Infarction Registry.
    Amann U; Kirchberger I; Heier M; Thilo C; Kuch B; Meisinger C
    Eur J Intern Med; 2018 Jan; 47():62-68. PubMed ID: 28826823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of in-hospital cardiac rehabilitation program on medication adherence and clinical outcomes in patients with acute myocardial infarction in the Lazio region of Italy.
    Soldati S; Di Martino M; Rosa AC; Fusco D; Davoli M; Mureddu GF
    BMC Cardiovasc Disord; 2021 Sep; 21(1):466. PubMed ID: 34565326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Diabetes Mellitus Status and Glycemic Control With Secondary Prevention Medication Adherence After Acute Myocardial Infarction.
    Adamek KE; Ramadurai D; Gunzburger E; Plomondon ME; Ho PM; Raghavan S
    J Am Heart Assoc; 2019 Feb; 8(3):e011448. PubMed ID: 30712488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological treatment after acute myocardial infarction from 2001 to 2006: a survey in Italian primary care.
    Filippi A; D'Ambrosio G; Giustini SE; Pecchioli S; Mazzaglia G; Cricelli C
    J Cardiovasc Med (Hagerstown); 2009 Sep; 10(9):714-8. PubMed ID: 19465867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients.
    Choudhry NK; Setoguchi S; Levin R; Winkelmayer WC; Shrank WH
    Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1189-96. PubMed ID: 18956426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
    Makam RC; Erskine N; McManus DD; Lessard D; Gore JM; Yarzebski J; Goldberg RJ
    Am J Cardiol; 2016 Dec; 118(12):1792-1797. PubMed ID: 27743577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal secondary prevention medication use in acute myocardial infarction patients with nonobstructive coronary artery disease is modified by management strategy: insights from the TRIUMPH Registry.
    Pitts R; Daugherty SL; Tang F; Jones P; Ho PM; Tsai TT; Spertus J; Maddox TM
    Clin Cardiol; 2017 Jun; 40(6):347-355. PubMed ID: 28387960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parabolas of medication use and discontinuation after myocardial infarction--are we closing the treatment gap?
    Hudson M; Richard H; Pilote L
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):773-85. PubMed ID: 17486661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of time-window bias on the assessment of the long-term effect of medication adherence: the case of secondary prevention after myocardial infarction.
    Di Martino M; Kirchmayer U; Agabiti N; Bauleo L; Fusco D; Perucci CA; Davoli M
    BMJ Open; 2015 Jun; 5(6):e007866. PubMed ID: 26063569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adherence to medication after myocardial infarction and its impact on outcome: a registry-based analysis from the Hungarian Myocardial Infarction Registry].
    Jánosi A; Ofner P; Kiss Z; Kiss L; Kiss RG; Dinnyés J; Járai Z; Nagy G; Veress G; Ferenci T
    Orv Hetil; 2017 Jul; 158(27):1051-1057. PubMed ID: 28670984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction.
    Lee JH; Bae MH; Yang DH; Park HS; Cho Y; Lee WK; Jeong MH; Kim YJ; Cho MC; Kim CJ; Chae SC;
    Korean J Intern Med; 2016 Mar; 31(2):267-76. PubMed ID: 26701233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction.
    Evans M; Carrero JJ; Szummer K; Åkerblom A; Edfors R; Spaak J; Jacobson SH; Andell P; Lindhagen L; Jernberg T
    J Am Coll Cardiol; 2016 Apr; 67(14):1687-97. PubMed ID: 27056774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.